We serve Chemical Name:2-chloro-1,3-thiazole-4-carbaldehyde CAS:5198-79-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-chloro-1,3-thiazole-4-carbaldehyde
CAS.NO:5198-79-8
Synonyms:4-Thiazolecarboxaldehyde,2-chloro;2-chlorothiazole-4-carbaldehyde;2-Chloro-4-formylthiazole;OR8404;2-chloro-4-thiazolecarboxaldehyde;2-Chlor-4-formyl-thiazol;2-Chloro-4-formyl-1,3-thiazole
Molecular Formula:C4H2ClNOS
Molecular Weight:147.58300
HS Code:2934100090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:278.6ºC at 760 mmHg
Density:1.541g/cm3
Index of Refraction:1.637
PSA:58.20000
Exact Mass:146.95500
LogP:1.60900
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4-Thiazolecarboxaldehyde,2-chloro chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Chloro-4-formyl-1,3-thiazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-chlorothiazole-4-carbaldehyde Use and application,2-Chloro-4-formylthiazole technical grade,usp/ep/jp grade.
Related News: ��With early evidence of clinical activity for our off-the-shelf, iPSC-derived NK cell programs, we are excited to lead in bringing next-generation CAR T-cell therapies to patients and plan to submit an IND for FT819 in the first half of 2020.�� 2-chloro-1,3-thiazole-4-carbaldehyde manufacturer In approving the first new Alzheimer’s drug in nearly 20 years, the U.S. Food and Drug Administration is taking its biggest risk yet with a strategy that allows new therapies onto the market without strong evidence that they work, regulatory and scientific experts say. 2-chloro-1,3-thiazole-4-carbaldehyde supplier Bristol-Myers Squibb (BMS) recently acquired Celgene, for example, which had the highest proportional R&D spend. 2-chloro-1,3-thiazole-4-carbaldehyde vendor Bristol-Myers Squibb (BMS) recently acquired Celgene, for example, which had the highest proportional R&D spend. 2-chloro-1,3-thiazole-4-carbaldehyde factory U.S. drugmaker Gilead dominates the HIV market and it will keep up the pressure with fast-growing Biktarvy, which was approved early last year.
